Cargando…

Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature

Background: The introduction of checkpoint inhibitors is a long-awaited new option for a urothelial cancer with a poor prognosis. Apart from clinical studies, the data on real world experience is scarce. Methods: Patients for monotherapy with either Atezolizumab, Nivolumab or Pembrolizumab after che...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fuhrmann, Christian, Struck, Julian P., Ivanyi, Philipp, Kramer, Mario W., Hupe, Marie C., Hensen, Bennet, Fürschke, Alexander, Peters, Inga, Merseburger, Axel S., Kuczyk, Markus A., von Klot, Christoph-A. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253725/ https://www.ncbi.nlm.nih.gov/pubmed/32528889 http://dx.doi.org/10.3389/fonc.2020.00808

Ejemplares similares

Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer
por: Hupe, Marie C., et al.
Publicado: (2020)

Incidence of synchronous and metachronous adrenal metastases following tumor nephrectomy in renal cell cancer patients: a retrospective bi-center analysis
por: Peters, Inga, et al.
Publicado: (2013)

Bicentric Retrospective Analysis of en Bloc Resection and Muscularis Mucosae Detection Rate in Non-Muscle Invasive Bladder Tumors: A Real-World Scenario
por: Struck, Julian P., et al.
Publicado: (2020)

Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy
por: von Klot, Christoph A., et al.
Publicado: (2017)

Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma
por: von Klot, Christoph-A, et al.
Publicado: (2014)

Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC)
por: Nicklas, André P., et al.
Publicado: (2018)

Decreased GATA5 mRNA expression associates with CpG island methylation and shortened recurrence-free survival in clear cell renal cell carcinoma
por: Peters, Inga, et al.
Publicado: (2014)

Clear-cell variant urothelial carcinoma of the bladder: a case report and review of the literature
por: Kramer, Mario W., et al.
Publicado: (2012)

First experiences using transurethral ultrasound ablation (TULSA) as a promising focal approach to treat localized prostate cancer: a monocentric study
por: Peters, Inga, et al.
Publicado: (2023)

Hemopatch(®) as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation
por: Hupe, Marie C., et al.
Publicado: (2020)

DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
por: Peters, Inga, et al.
Publicado: (2014)

New computed tomographic predictors of complicated perioperative course of 17.5F mini-percutaneous nephrolithotomy (mini-PNL)
por: Ozimek, Tomasz, et al.
Publicado: (2020)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
por: Bamias, Aristotelis, et al.
Publicado: (2023)

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
por: Merseburger, Axel S., et al.
Publicado: (2016)

Impact of sarcopenia in advanced and metastatic soft tissue sarcoma
por: Strassmann, Dennis, et al.
Publicado: (2021)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Reduced mrna expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer
por: Tezval, Hossein, et al.
Publicado: (2013)

GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma
por: PETERS, INGA, et al.
Publicado: (2014)

Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinoma
por: Brown, Jason R., et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer
por: Zhu, Alec, et al.
Publicado: (2023)

Development of a clinical algorithm for treating urethral strictures based on a large retrospective single-center cohort
por: Tolkach, Yuri, et al.
Publicado: (2017)

Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response
por: Dubrowinskaja, Natalia, et al.
Publicado: (2014)

RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma
por: Tezval, Hossein, et al.
Publicado: (2008)

Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor
por: Chiang, Ryan S., et al.
Publicado: (2020)

Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Hong, Joohyun, et al.
Publicado: (2022)

Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data
por: Fischer, Christine, et al.
Publicado: (2020)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
por: Kawahara, Takashi, et al.
Publicado: (2023)

The dilemma of 12/14F ureteral access sheath (UAS) usage: a case control study
por: Ozimek, Tomasz, et al.
Publicado: (2022)

DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers
por: Katzendorn, Olga, et al.
Publicado: (2021)

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
por: Shabto, Julie M., et al.
Publicado: (2020)

Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy
por: Lindner, Andrea Katharina, et al.
Publicado: (2023)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
por: Grünwald, Viktor, et al.
Publicado: (2012)

Metastatic urothelial carcinoma()()
por: Gómez-Moyano, Elisabeth, et al.
Publicado: (2021)

ShinyLUTS—A Shiny web application for structured data management and analysis for patients with lower urinary tract symptoms (LUTS)
por: von Klot, Christoph-Alexander Joachim, et al.
Publicado: (2023)

First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice
por: Naito, Renato, et al.
Publicado: (2020)

Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
por: Nuzzo, Pier Vitale, et al.
Publicado: (2020)

Current perspectives on novel systemic therapeutic agents beyond immune checkpoint inhibition in metastatic urothelial carcinoma
por: Choi, Hoon, et al.
Publicado: (2020)

Clinical outcomes of immune checkpoint inhibitor plus nab-paclitaxel in metastatic upper tract urothelial carcinoma
por: Su, Ruopeng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_793gv1sihbb8m222lq6m0u9lnv